EMA Approval and Product Identity

The European Union Executive Committee approved SomaKit TOC (generic name edotreotide) from Advanced Accelerator Applications for sale on December 8, 2016. Gallium-68-labeled edotreotide binds to somatostatin receptors (SSTR), particularly SSTR2, and is a marketed diagnostic agent for identifying primary lesions and metastases in adult patients with confirmed or suspected well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET) using PET. The approval was finalized following a positive opinion from the CHMP on September 15, 2016, and the orphan drug designation granted on March 19, 2015, remains in effect.

Literature-Based Clinical Evidence

This approval was based not on a traditional single Phase 3 trial, but on a synthesis of multiple published studies and established medical use data, including 970 patients and 977 examinations. In EMA evaluation, the sensitivity per study ranged from 92.8–100%, specificity from 89–100%, and lesion detection rate was approximately 75%, recognizing the diagnostic performance and low safety burden. This is not a conditional signal from a clinical development asset, but a marketed radiopharmaceutical at the approval and commercialization stage, supporting staging and selection of patients for peptide receptor radionuclide therapy (PRRT) by simultaneously confirming SSTR expression and whole-body lesion distribution.

Competitive Landscape and Theranostics Link

At the time, the standard competitive method was OctreoScan SPECT based on indium-111 pentetreotide. Currently, direct competitive PET tracers include Netspot based on gallium-68 dotatate and Detectnet based on copper-64 dotatate. The high resolution and short examination time of the same SSTR imaging platform became the basis for shifting diagnostic demand from SPECT to PET. The key is the diagnostic–therapeutic system connecting positive patients to Lutathera (lutetium-177 dotatate), an SSTR2-targeted therapeutic agent. Lutathera generated USD 816M in revenue for Novartis (NVS) in 2025.

Ownership and Market Implications

Novartis (NVS) conducted a cash acquisition of AAA through a public tender offer in January 2018, with a cash consideration of USD 3.9B on a fully diluted basis. The current EMA marketing authorization holder is Novartis Europharm Limited. The product approved by the U.S. FDA on August 21, 2019, is not branded as SomaKit TOC, but as Ga 68 DOTATOC Injection from the University of Iowa Health Care, with adult and pediatric SSTR-positive NET as the indication. The global NET treatment market is projected to grow from USD 2.87B in 2025 to USD 4.89B in 2034, making the value of the radiopharmaceutical theranostics platform—converting diagnostic sales into therapeutic revenue—greater than the imaging agent itself.